Does the media prefer MRKR or PEPG?

In the previous week, PepGen had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Marker Therapeutics. PepGen's average media sentiment score of 0.51 beat Marker Therapeutics' score of 0.30 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MRKR or BMEA?

In the previous week, Biomea Fusion had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Marker Therapeutics. Biomea Fusion's average media sentiment score of 0.62 beat Marker Therapeutics' score of 0.30 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRKR or LFVN?

In the previous week, Lifevantage had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Lifevantage and 1 mentions for Marker Therapeutics. Lifevantage's average media sentiment score of 0.55 beat Marker Therapeutics' score of 0.30 indicating that Lifevantage is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lifevantage 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MRKR or VRCA?

In the previous week, Marker Therapeutics and Marker Therapeutics both had 1 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 0.63 beat Marker Therapeutics' score of 0.30 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MRKR or PMN?

In the previous week, Marker Therapeutics and Marker Therapeutics both had 1 articles in the media. Promis Neurosciences' average media sentiment score of 0.63 beat Marker Therapeutics' score of 0.30 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Marker Therapeutics (MRKR) Competitors

$1.48 +0.03 (+2.21%)

As of 03:28 PM Eastern

Compare

MRKR vs. PEPG, BMEA, LFVN, VRCA, and PMN

Should you buy Marker Therapeutics stock or one of its competitors? MarketBeat compares Marker Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marker Therapeutics include PepGen (PEPG), Biomea Fusion (BMEA), Lifevantage (LFVN), Verrica Pharmaceuticals (VRCA), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.

How does Marker Therapeutics compare to PepGen?

Marker Therapeutics (NASDAQ:MRKR) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Marker Therapeutics has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market. Comparatively, PepGen has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

PepGen has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. PepGen's return on equity of -59.89% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
PepGen	N/A	-59.89%	-49.62%

Marker Therapeutics has higher revenue and earnings than PepGen. Marker Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	7.02	-$12.16M	-$0.61	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

In the previous week, PepGen had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Marker Therapeutics. PepGen's average media sentiment score of 0.51 beat Marker Therapeutics' score of 0.30 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Marker Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 568.90%. PepGen has a consensus target price of $11.60, indicating a potential upside of 691.81%. Given PepGen's stronger consensus rating and higher possible upside, analysts clearly believe PepGen is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

PepGen beats Marker Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to Biomea Fusion?

Marker Therapeutics (NASDAQ:MRKR) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Marker Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

Marker Therapeutics has higher revenue and earnings than Biomea Fusion. Marker Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	7.02	-$12.16M	-$0.61	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

In the previous week, Biomea Fusion had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Marker Therapeutics. Biomea Fusion's average media sentiment score of 0.62 beat Marker Therapeutics' score of 0.30 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by insiders. Comparatively, 10.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Biomea Fusion has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Biomea Fusion	N/A	-265.37%	-103.96%

Marker Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 568.90%. Biomea Fusion has a consensus price target of $8.50, indicating a potential upside of 518.18%. Given Marker Therapeutics' higher possible upside, equities research analysts clearly believe Marker Therapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Biomea Fusion beats Marker Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to Lifevantage?

Marker Therapeutics (NASDAQ:MRKR) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Lifevantage has a net margin of 2.94% compared to Marker Therapeutics' net margin of -343.03%. Lifevantage's return on equity of 23.89% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Lifevantage	2.94%	23.89%	12.47%

Marker Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 568.90%. Lifevantage has a consensus price target of $5.00, indicating a potential downside of 47.51%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Marker Therapeutics is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 35.3% of Lifevantage shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 22.0% of Lifevantage shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Marker Therapeutics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Lifevantage has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Lifevantage has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	7.02	-$12.16M	-$0.61	N/A
Lifevantage	$195.32M	0.62	$9.81M	$0.45	21.17

In the previous week, Lifevantage had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Lifevantage and 1 mentions for Marker Therapeutics. Lifevantage's average media sentiment score of 0.55 beat Marker Therapeutics' score of 0.30 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifevantage	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lifevantage beats Marker Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Marker Therapeutics (NASDAQ:MRKR) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Verrica Pharmaceuticals has a net margin of -47.97% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

In the previous week, Marker Therapeutics and Marker Therapeutics both had 1 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 0.63 beat Marker Therapeutics' score of 0.30 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Marker Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 568.90%. Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 136.93%. Given Marker Therapeutics' higher probable upside, research analysts plainly believe Marker Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Marker Therapeutics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Marker Therapeutics has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	7.02	-$12.16M	-$0.61	N/A
Verrica Pharmaceuticals	$35.58M	2.96	-$17.89M	-$1.03	N/A

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Verrica Pharmaceuticals beats Marker Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Marker Therapeutics compare to Promis Neurosciences?

Marker Therapeutics (NASDAQ:MRKR) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

In the previous week, Marker Therapeutics and Marker Therapeutics both had 1 articles in the media. Promis Neurosciences' average media sentiment score of 0.63 beat Marker Therapeutics' score of 0.30 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Marker Therapeutics has higher revenue and earnings than Promis Neurosciences. Marker Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	7.02	-$12.16M	-$0.61	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Promis Neurosciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Promis Neurosciences	N/A	-237.99%	-151.04%

Marker Therapeutics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market.

Marker Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 568.90%. Promis Neurosciences has a consensus target price of $26.50, indicating a potential upside of 167.95%. Given Marker Therapeutics' higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Promis Neurosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Marker Therapeutics beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRKR vs. The Competition

Export

Metric	Marker Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.92M	$2.96B	$6.42B	$12.48B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-2.45	18.04	23.85	24.39
Price / Sales	7.02	296.06	520.29	116.29
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	1.48	3.92	10.04	6.74
Net Income	-$12.16M	$75.85M	$3.56B	$337.03M
7 Day Performance	-0.99%	-2.17%	-1.09%	0.13%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-0.99%	22.51%	28.56%	34.29%

Marker Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRKR Marker Therapeutics	2.2395 of 5 stars	$1.48 +2.2%	$10.00 +574.8%	-4.6%	$24.71M	$3.55M	N/A	60	Short Interest Increase
PEPG PepGen	2.8181 of 5 stars	$1.43 -5.0%	$11.60 +714.0%	-7.2%	$103.75M	N/A	N/A	30	Analyst Downgrade
BMEA Biomea Fusion	2.0348 of 5 stars	$1.43 +3.3%	$8.29 +481.5%	-47.8%	$99.77M	N/A	N/A	50
LFVN Lifevantage	2.9778 of 5 stars	$9.48 +20.4%	$5.00 -47.2%	-35.3%	$99.29M	$228.53M	23.07	260	Ex-Dividend High Trading Volume
VRCA Verrica Pharmaceuticals	2.8282 of 5 stars	$6.03 +4.6%	$14.50 +140.7%	+10.5%	$98.95M	$37.16M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRKR) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marker Therapeutics (MRKR) Competitors

MRKR vs. PEPG, BMEA, LFVN, VRCA, and PMN

How does Marker Therapeutics compare to PepGen?

Summary

How does Marker Therapeutics compare to Biomea Fusion?

Summary

How does Marker Therapeutics compare to Lifevantage?

Summary

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Marker Therapeutics compare to Promis Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marker Therapeutics (MRKR) Competitors

MRKR vs. PEPG, BMEA, LFVN, VRCA, and PMN

How does Marker Therapeutics compare to PepGen?

Which has more volatility & risk, MRKR or PEPG?

Is MRKR or PEPG more profitable?

Which has preferable earnings and valuation, MRKR or PEPG?

Does the media prefer MRKR or PEPG?

Do analysts recommend MRKR or PEPG?

Do institutionals & insiders have more ownership in MRKR or PEPG?

Summary

How does Marker Therapeutics compare to Biomea Fusion?

Which has more risk and volatility, MRKR or BMEA?

Which has stronger valuation and earnings, MRKR or BMEA?

Does the media favor MRKR or BMEA?

Do institutionals and insiders have more ownership in MRKR or BMEA?

Is MRKR or BMEA more profitable?

Do analysts recommend MRKR or BMEA?

Summary

How does Marker Therapeutics compare to Lifevantage?

Is MRKR or LFVN more profitable?

Do analysts recommend MRKR or LFVN?

Do institutionals & insiders have more ownership in MRKR or LFVN?

Which has more risk & volatility, MRKR or LFVN?

Which has stronger earnings and valuation, MRKR or LFVN?

Does the media refer more to MRKR or LFVN?

Summary

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Is MRKR or VRCA more profitable?

Does the media prefer MRKR or VRCA?

Do analysts prefer MRKR or VRCA?

Which has more volatility and risk, MRKR or VRCA?

Which has preferable earnings & valuation, MRKR or VRCA?

Do institutionals & insiders hold more shares of MRKR or VRCA?

Summary

How does Marker Therapeutics compare to Promis Neurosciences?

Does the media prefer MRKR or PMN?

Which has stronger earnings & valuation, MRKR or PMN?

Do institutionals and insiders believe in MRKR or PMN?

Is MRKR or PMN more profitable?

Which has more volatility & risk, MRKR or PMN?

Do analysts prefer MRKR or PMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools